100 related articles for article (PubMed ID: 1923154)
1. Relationship between 99Tcm-MDP uptake and bone mineral density in patients with prostatic carcinoma.
Sundkvist GM; Nilsson M; Ahlgren L; Lilja B; Mattsson S; Birch-Iensen M; Abrahamsson PA
Nucl Med Commun; 1991 Jul; 12(7):629-36. PubMed ID: 1923154
[TBL] [Abstract][Full Text] [Related]
2. Dynamic quantitative bone scintigraphy in patients with prostatic carcinoma treated by orchiectomy.
Sundkvist GM; Ahlgren L; Lilja B; Mattsson S; Abrahamsson PA
Eur J Nucl Med; 1990; 16(8-10):671-6. PubMed ID: 2384103
[TBL] [Abstract][Full Text] [Related]
3. Additional information from quantitative 24-hour 99mTc-MDP bone scintigraphy in patients with prostatic carcinoma.
Sundkvist GM; Ahlgren L; Lilja B; Mattsson S
Acta Oncol; 1991; 30(5):635-9. PubMed ID: 1892682
[TBL] [Abstract][Full Text] [Related]
4. Repeated quantitative bone scintigraphy in patients with prostatic carcinoma treated with orchiectomy.
Sundkvist GM; Ahlgren L; Lilja B; Mattsson S; Abrahamsson PA; Wadström LB
Eur J Nucl Med; 1988; 14(4):203-6. PubMed ID: 3169056
[TBL] [Abstract][Full Text] [Related]
5. The relation of radionuclide uptake by bone to the rate of calcium mineralization. II: Patient studies using 99Tcm-MDP.
Budd RS; Hodgson GS; Hare WS
Br J Radiol; 1989 Apr; 62(736):318-20. PubMed ID: 2713589
[TBL] [Abstract][Full Text] [Related]
6. Lumbar bone mineral density in prostate cancer patients with bone metastases.
Chang CH; Tsai CS; Jim YF; Wu HC; Lin CC; Kao A
Endocr Res; 2003 May; 29(2):177-82. PubMed ID: 12856804
[TBL] [Abstract][Full Text] [Related]
7. Enhanced uptake of 99Tcm-MDP in skeletal metastases from prostate cancer following initiation of hormone treatment: potential for increasing delivery of therapeutic agents.
Bushnell DL; Madsen M; Kahn D; Nathan M; Williams RD
Nucl Med Commun; 1999 Oct; 20(10):875-81. PubMed ID: 10528290
[TBL] [Abstract][Full Text] [Related]
8. Quantitative bone scintigraphy and 24-hour whole-body counting of 99mTc-methylene diphosphonate in patients with prostatic carcinoma.
Sundkvist GM; Ahlgren L; Lilja B; Mattsson S
Nuklearmedizin; 1992 Oct; 31(5):178-81. PubMed ID: 1465355
[TBL] [Abstract][Full Text] [Related]
9. 99Tcm-MDP and 99Tcm-DPD in pathologic bone lesions. A visual and quantitative comparison.
Lantto T; Vorne M; Mokka R; Vähätalo S
Acta Radiol; 1987; 28(5):631-3. PubMed ID: 2960361
[TBL] [Abstract][Full Text] [Related]
10. Clinical comparison of bone scintigraphy with 99Tcm-DPD, 99Tcm-HDP and 99Tcm-MDP.
Bergqvist L; Brismar J; Cederquist E; Darte L; Naversten Y; Palmer J
Acta Radiol Diagn (Stockh); 1984; 25(3):217-23. PubMed ID: 6236672
[TBL] [Abstract][Full Text] [Related]
11. Quantitative bone scintigraphy in prostatic carcinoma--long-term response to treatment.
Sundkvist GM; Ahlgren L; Lilja B; Mattsson S
Nuklearmedizin; 1993 Oct; 32(5):231-5. PubMed ID: 8233843
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of technetium-99m methylene diphosphonate myocardial uptake: association with carcinoma of the prostate.
al-Nahhas AM; Jinnouchi S; Anagnostopoulos C; Hirsch W; Heary T; McCready VR
Eur J Nucl Med; 1995 Feb; 22(2):148-53. PubMed ID: 7758502
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of the bone marrow imaging agent 99Tcm-phytate in the detection of bone metastases.
Chang CP; Liu RS; Yu SM; Wynchank S; Chu LS; Shiau HY; Cheng TC
Nucl Med Commun; 1996 Dec; 17(12):1030-4. PubMed ID: 9004298
[TBL] [Abstract][Full Text] [Related]
14. Soft-tissue uptake of technetium-99m-MDP after prostate cryoablation.
Zucker I; Charkes ND; Seidmon EJ; Maurer AH
J Nucl Med; 1997 Apr; 38(4):525-8. PubMed ID: 9098195
[TBL] [Abstract][Full Text] [Related]
15. Correlation between BMD and bone scintigraphy in patients with prostate cancer.
Perk H; Yildiz M; Kosar A; Cerci S; Soyupek F; Ozorak A; Dilmen C
Urol Oncol; 2008; 26(3):250-3. PubMed ID: 18452814
[TBL] [Abstract][Full Text] [Related]
16. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
[TBL] [Abstract][Full Text] [Related]
17. Detection of metastatic bone lesions in patients with prostate carcinoma: 99Tcm-monoclonal antibody imaging.
Kiraç S; Duman Y; Cüreklibatur I; Yüksel D; Nazli O; Günaydin G; Taner M
Nucl Med Commun; 1997 Oct; 18(10):968-73. PubMed ID: 9392800
[TBL] [Abstract][Full Text] [Related]
18. Effects of 99mTc-MIBI and 99mTc-MDP administration on dual-energy X-ray absorptiometry bone mineral density measurements.
Gumuser G; Parlak Y; Topal G; Aras F; Ruksen E; Sayit E
Nucl Med Commun; 2009 Jun; 30(6):445-8. PubMed ID: 19357550
[TBL] [Abstract][Full Text] [Related]
19. 16 detector multislice CT versus skeletal scintigraphy in the diagnosis of wrist fractures: value of quantification of 99Tcm-MDP uptake.
Groves AM; Cheow HK; Balan KK; Bearcroft PW; Dixon AK
Br J Radiol; 2005 Sep; 78(933):791-5. PubMed ID: 16110099
[TBL] [Abstract][Full Text] [Related]
20. Antecedent 99mTc-MDP and 99mTc-sestamibi administration corrupts bone mineral density measured by DXA.
McKiernan FE; Hocking J; Cournoyer S
J Clin Densitom; 2006; 9(2):164-6. PubMed ID: 16785076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
